- Page 1 and 2: Immunotherapy for Infectious Diseas
- Page 3 and 4: In f e c t i o u s . D i s e a s e
- Page 5 and 6: © 2002 Humana Press Inc. 999 River
- Page 7 and 8: vi Preface I am grateful to all of
- Page 9 and 10: viii Contents 11 Passive Immunother
- Page 11 and 12: x Contributors BARBARA G. MATTHEWS,
- Page 14 and 15: From: Immunotherapy for Infectious
- Page 16 and 17: Humoral Immunity 5 Fig. 1. Humoral
- Page 18 and 19: Humoral Immunity 7 Table 1 Properti
- Page 20 and 21: Humoral Immunity 9 minal complement
- Page 22 and 23: Humoral Immunity 11 ficity. In ligh
- Page 24 and 25: Humoral Immunity 13 Fig. 7. VDJ joi
- Page 28 and 29: Humoral Immunity 17 In contrast to
- Page 30 and 31: Humoral Immunity 19 advantage to tr
- Page 32 and 33: Humoral Immunity 21 32. Allman DM,
- Page 34 and 35: Some Basic Cellular Immunology Prin
- Page 36 and 37: Cellular Immunology Principles 25 i
- Page 38 and 39: Cellular Immunology Principles 27 s
- Page 40 and 41: Cellular Immunology Principles 29 d
- Page 42 and 43: Cellular Immunology Principles 31 f
- Page 44 and 45: Cellular Immunology Principles 33 F
- Page 46 and 47: Cellular Immunology Principles 35 R
- Page 48 and 49: Cellular Immunology Principles 37 1
- Page 50 and 51: INTRODUCTION Immune Defense at Muco
- Page 52 and 53: Immune Defense at Mucosal Surfaces
- Page 54 and 55: Immune Defense at Mucosal Surfaces
- Page 56 and 57: Immune Defense at Mucosal Surfaces
- Page 58 and 59: Immune Defense at Mucosal Surfaces
- Page 60 and 61: Immune Defense at Mucosal Surfaces
- Page 62 and 63: Immune Defense at Mucosal Surfaces
- Page 64 and 65: Immune Defense at Mucosal Surfaces
- Page 66 and 67: Immune Defense at Mucosal Surfaces
- Page 68 and 69: Immune Defense at Mucosal Surfaces
- Page 70 and 71: Immune Defense at Mucosal Surfaces
- Page 72: II Molecular Basis for Immunotherap
- Page 75 and 76: 64 Kunert and Katinger IMMUNOGLOBUL
- Page 77 and 78:
66 Fig. 2. Monomeric, dimeric, and
- Page 79 and 80:
68 Kunert and Katinger Fig. 4. Humo
- Page 81 and 82:
70 Kunert and Katinger remove prote
- Page 83 and 84:
72 Kunert and Katinger Fig. 6. Diff
- Page 85 and 86:
74 Kunert and Katinger persons of a
- Page 87 and 88:
76 Kunert and Katinger that so-call
- Page 89 and 90:
78 Kunert and Katinger whereas sele
- Page 91 and 92:
80 Kunert and Katinger Different pr
- Page 93 and 94:
82 Kunert and Katinger HUMAN/MOUSE
- Page 95 and 96:
84 Kunert and Katinger are expresse
- Page 97 and 98:
86 Kunert and Katinger missing meta
- Page 99 and 100:
88 Kunert and Katinger Fig. 8. Sche
- Page 101 and 102:
90 Kunert and Katinger include a se
- Page 103 and 104:
92 Kunert and Katinger 32. Lee S, e
- Page 105 and 106:
94 Kunert and Katinger 72. Abbs IC,
- Page 107 and 108:
96 Kunert and Katinger 117. Wright
- Page 110 and 111:
From: Immunotherapy for Infectious
- Page 112 and 113:
Dendritic Cells 101 several organis
- Page 114 and 115:
Dendritic Cells 103 tion that infec
- Page 116 and 117:
Dendritic Cells 105 chaperones such
- Page 118 and 119:
Dendritic Cells 107 CD8� CTLs, th
- Page 120 and 121:
Dendritic Cells 109 complete tumor
- Page 122 and 123:
Dendritic Cells 111 19. Holland SM,
- Page 124 and 125:
Dendritic Cells 113 mouse pneumonit
- Page 126 and 127:
Dendritic Cells 115 dendritic cells
- Page 128 and 129:
INTRODUCTION Cytokines, Cytokine An
- Page 130 and 131:
Cytokines, Cytokine Antagonists, an
- Page 132 and 133:
Cytokines, Cytokine Antagonists, an
- Page 134 and 135:
Cytokines, Cytokine Antagonists, an
- Page 136 and 137:
Cytokines, Cytokine Antagonists, an
- Page 138 and 139:
Cytokines, Cytokine Antagonists, an
- Page 140 and 141:
Principles of Vaccine Development F
- Page 142 and 143:
Principles of Vaccine Development 1
- Page 144 and 145:
Principles of Vaccine Development 1
- Page 146 and 147:
Principles of Vaccine Development 1
- Page 148 and 149:
Principles of Vaccine Development 1
- Page 150 and 151:
Principles of Vaccine Development 1
- Page 152 and 153:
Principles of Vaccine Development 1
- Page 154 and 155:
Principles of Vaccine Development 1
- Page 156 and 157:
Principles of Vaccine Development 1
- Page 158:
Principles of Vaccine Development 1
- Page 162 and 163:
INTRODUCTION Immunopathogenesis of
- Page 164 and 165:
Immunopathogenesis of HIV Disease 1
- Page 166 and 167:
Immunopathogenesis of HIV Disease 1
- Page 168 and 169:
Immunopathogenesis of HIV Disease 1
- Page 170 and 171:
Immunopathogenesis of HIV Disease 1
- Page 172:
Immunopathogenesis of HIV Disease 1
- Page 175 and 176:
164 Connick counts ranged from 73 t
- Page 177 and 178:
166 Connick retinitis in an individ
- Page 179 and 180:
168 Connick A novel method of ident
- Page 181 and 182:
170 Connick occurs quite early in i
- Page 183 and 184:
172 Connick 2. Delta Coordinating C
- Page 185 and 186:
174 Connick 39. Hurni MA, Bohlen L,
- Page 187 and 188:
176 Connick 76. Dolan M.J., Clerici
- Page 189 and 190:
178 Connick 114. Komanduri KV, Visw
- Page 192 and 193:
From: Immunotherapy for Infectious
- Page 194 and 195:
Active Immunization for HIV Infecti
- Page 196 and 197:
Active Immunization for HIV Infecti
- Page 198 and 199:
Active Immunization for HIV Infecti
- Page 200 and 201:
Active Immunization for HIV Infecti
- Page 202 and 203:
Active Immunization for HIV Infecti
- Page 204 and 205:
Active Immunization for HIV Infecti
- Page 206 and 207:
Active Immunization for HIV Infecti
- Page 208:
Active Immunization for HIV Infecti
- Page 211 and 212:
200 Jacobson changes of gp120 alter
- Page 213 and 214:
202 Jacobson is reduced (54,55). A
- Page 215 and 216:
204 Jacobson Table 2 Potential Prot
- Page 217 and 218:
206 Jacobson from the SIV/17E-Cl-in
- Page 219 and 220:
208 Jacobson Several groups have de
- Page 221 and 222:
210 Jacobson HUMAN STUDIES Polyclon
- Page 223 and 224:
212 Jacobson clinical isolates, whi
- Page 225 and 226:
214 Jacobson 22. Beasley RP, Hwang
- Page 227 and 228:
216 Jacobson 59. Yoshiyama H, Mo H,
- Page 229 and 230:
218 Jacobson 95. Prince AM, Reesink
- Page 231 and 232:
220 Jacobson 133. Stiehm ER, Lamber
- Page 233 and 234:
222 Kilby and Bucy Although clinica
- Page 235 and 236:
224 Kilby and Bucy can infect human
- Page 237 and 238:
226 Kilby and Bucy the proinflammat
- Page 239 and 240:
228 Kilby and Bucy CD3/CD28, and th
- Page 241 and 242:
230 Kilby and Bucy of viral replica
- Page 243 and 244:
232 Kilby and Bucy 21. Cao Y, Qin L
- Page 245 and 246:
234 Kilby and Bucy 64. Pantaleo G,
- Page 247 and 248:
236 Kilby and Bucy 101. Clements-Ma
- Page 249 and 250:
238 Dornburg and Pomerantz cells (5
- Page 251 and 252:
240 Dornburg and Pomerantz Fig. 2.
- Page 253 and 254:
242 Dornburg and Pomerantz domains
- Page 255 and 256:
244 Dornburg and Pomerantz GENETIC
- Page 257 and 258:
246 Dornburg and Pomerantz Fig. 5.
- Page 259 and 260:
248 Dornburg and Pomerantz 6. Balti
- Page 262 and 263:
From: Immunotherapy for Infectious
- Page 264 and 265:
Viral Infections Other than HIV 253
- Page 266 and 267:
Viral Infections Other than HIV 255
- Page 268 and 269:
Viral Infections Other than HIV 257
- Page 270 and 271:
From: Immunotherapy for Infectious
- Page 272 and 273:
Virus-Associated Malignancies 261 c
- Page 274 and 275:
Virus-Associated Malignancies 263 o
- Page 276 and 277:
Virus-Associated Malignancies 265 I
- Page 278 and 279:
Virus-Associated Malignancies 267 R
- Page 280 and 281:
Virus-Associated Malignancies 269 T
- Page 282 and 283:
Virus-Associated Malignancies 271 1
- Page 284 and 285:
Virus-Associated Malignancies 273 5
- Page 286 and 287:
From: Immunotherapy for Infectious
- Page 288 and 289:
Bacterial Infections and Sepsis 277
- Page 290 and 291:
Bacterial Infections and Sepsis 279
- Page 292:
Bacterial Infections and Sepsis 281
- Page 295 and 296:
284 Wallis and Johnson replication
- Page 297 and 298:
286 Wallis and Johnson Several stud
- Page 299 and 300:
288 Wallis and Johnson monocytes, a
- Page 301 and 302:
290 Wallis and Johnson peripheral b
- Page 303 and 304:
292 Wallis and Johnson (A. Hise and
- Page 305 and 306:
294 Wallis and Johnson infections,
- Page 307 and 308:
296 Wallis and Johnson 37. Boom WH.
- Page 309 and 310:
298 Wallis and Johnson 77. Ellner J
- Page 311 and 312:
300 Wallis and Johnson 113. Raad I,
- Page 313 and 314:
302 Wallis and Johnson 154. Anonymo
- Page 315 and 316:
304 Table 1 Major Fungal Infections
- Page 317 and 318:
306 Casadevall species suggest that
- Page 319 and 320:
308 Casadevall transfusions from G-
- Page 321 and 322:
310 Casadevall Table 3 Augmentation
- Page 323 and 324:
312 Casadevall There has been some
- Page 325 and 326:
314 Casadevall effective in achievi
- Page 327 and 328:
316 Casadevall CONCLUSION AND FUTUR
- Page 329 and 330:
318 Casadevall 16. Boutati EI, Anai
- Page 331 and 332:
320 Casadevall 52. Gallin JI, Malec
- Page 333 and 334:
322 Casadevall 91. Kowanko IC, Ferr
- Page 335 and 336:
324 Index Blastomycosis, see Fungal
- Page 337 and 338:
326 Index C-type retrovirus vectors
- Page 339 and 340:
328 Index K Klebsiella, intravenous
- Page 341 and 342:
330 Index Vaccine Recombinant vecto
- Page 343:
Infectious Disease IMMUNOTHERAPY FO